Who is a candidate for ChondroFiller injection instead of hip replacement?

For many patients, the conversation shifts abruptly: physiotherapy has plateaued, steroid injections are no longer helping, and a consultant has raised the possibility of total hip replacement (THR). For those who are not ready for that step — whether because of age, fitness, or personal choice — a joint-preservation pathway using ChondroFiller injection may offer a meaningful bridge.

Three broad groups of patients tend to reach this point. First, those in their 40s or 50s for whom a hip replacement is technically feasible but carries a realistic risk of outlasting the implant — requiring a more complex revision procedure within their lifetime. Second, older patients who are medically unsuitable for general anaesthesia or major surgery, where the risk-to-benefit balance of an outpatient ultrasound-guided injection looks more favourable than a theatre-based operation. Third, patients of any age who are motivated to preserve their own joint tissue and are prepared to commit to a regenerative approach rather than a replacement.

What unites these groups is not age but the character of the cartilage damage: ChondroFiller injection is designed for focal, full-thickness lesions rather than end-stage, bone-on-bone arthritis affecting the whole joint surface. Older patients are not automatically excluded — the critical question is whether significant joint space remains.

The specific defect-size and imaging criteria that determine suitability are set out in the section below.

How ChondroFiller injection works in the hip joint

The injection itself contains no living cells and no donor tissue — ChondroFiller is a CE-marked, cell-free type I collagen hydrogel, a biological scaffold material rather than a drug. Delivered into the hip joint under ultrasound guidance as an outpatient procedure with local anaesthetic, it self-gels within three to five minutes on contact with the joint environment, settling over the worn cartilage surface without the need for a theatre, general anaesthetic, or surgical incision.

Once set, the scaffold acts as a temporary framework — think of it as biological scaffolding erected so the body can carry out its own building work. The matrix recruits the patient's own progenitor cells, drawn from the surrounding synovium and underlying subchondral bone, which migrate into the scaffold and support new tissue formation. This process is known as acellular matrix-induced chondrogenesis: the product provides the structural environment; the patient's biology does the repair.

It is worth being precise about what ChondroFiller injection is not. It is not a painkiller, so there is no immediate analgesic effect to expect in the first days. It is not a lubricant or viscosupplement — unlike hyaluronic acid injections, it does not simply coat the joint to reduce friction. And it is not a permanent synthetic filler occupying the defect indefinitely; the scaffold is a temporary biological medium through which endogenous repair is intended to progress.

In published hip cases, MRI at 12 months has confirmed progressive tissue maturation within the treated area, providing an objective measure of how the scaffold integrates over time rather than an immediate clinical marker.

What the clinical evidence shows for hip applications

Two prospective cohort studies published in 2021 provide the most substantive published evidence for ChondroFiller in the hip.

Mazek et al. (PMC8460160) followed 26 adults with acetabular cartilage lesions greater than 2 cm² for between 12 and 60 months. Of 21 evaluable patients at 3–5 years, 17 achieved good or excellent outcomes; only 2 subsequently required total hip replacement. Published outcome anchors for hip cases sit at approximately +33 points on the Harris Hip Score and MOCART MRI regeneration scores of 70–87, with tissue maturation confirmed on MRI at 12 months — a meaningful signal for a condition where progressive functional decline is the natural course. One point of context on the study design: the Mazek data were generated using arthroscopic placement, not the image-guided outpatient injection route used in the current clinical pathway. The scaffold evidence stands on its own; the delivery conditions differed from today's injectable approach.

The critical limitation embedded in those otherwise encouraging figures is baseline joint status. Patients with pre-existing Tönnis grade 2–3 osteoarthritis had poor outcomes in the Mazek cohort — a finding that applies regardless of delivery route and should carry real weight in the assessment of any patient presenting with more diffuse or advanced joint wear.

Perez-Carro et al. (PMC8322278) independently described injectable ChondroFiller liquid as a viable procedure for full-thickness acetabular defects, reporting promising early results. The authors were explicit that longer-term studies on larger cohorts are required before the evidence can be generalised — a reasonable characterisation of where the field currently stands.

Both studies are prospective cohorts, not randomised controlled trials. No head-to-head comparison between ChondroFiller injection and other injectables or total hip replacement has been published. Published symptom-relief rates of approximately 70–85% should be read against that evidence level rather than as a guaranteed benchmark.

The combined injection protocol for older patients with more advanced hip OA

For patients in their 60s or older whose imaging shows Kellgren-Lawrence Grade III or IV changes — meaning more diffuse wear across the joint rather than a single focal lesion — the standard ChondroFiller injection protocol may be extended into a combined dual-injection approach.

In this model, ChondroFiller (2.3 mL) is directed at the exposed cartilage surfaces at the bone ends, where it self-gels and provides the regenerative scaffold function: recruiting the patient's own cells to support tissue repair. A separate injection of Arthrosamid — a non-regenerative polyacrylamide hydrogel (6 mL) — is delivered to target the synovial membrane, where it acts as a longer-lasting cushioning medium to modulate the joint environment. These are two distinct products performing two distinct roles. ChondroFiller is the scaffold component supporting endogenous repair; Arthrosamid is a permanent synthetic hydrogel that does not regenerate cartilage and works through a different mechanism entirely. They should not be described as a single blended treatment, because conflating them would misrepresent both.

The combined approach is described as additive — both injections are placed under image guidance in a fluid joint environment, without the debridement, dry-joint conditions, or anaesthesia that arthroscopic cartilage repair demands.

Because advanced OA is rarely resolved by a single intervention, this clinical model includes a structured maintenance commitment: 2-yearly ChondroFiller top-up injections and annual MRI review to monitor joint status over time, rather than treating the initial procedure as a one-off fix.

Patients considering this pathway should know that it sits ahead of published trial evidence. The rationale is mechanistic — two complementary mechanisms addressing different anatomical targets — but a randomised controlled trial in KL Grade III/IV hip OA patients receiving this specific combined protocol does not yet exist. That means the approach rests on clinical reasoning and practice experience rather than the highest tier of proof, which is worth weighing alongside the non-surgical nature of the procedure.

Candidacy criteria, realistic expectations, and evidence gaps

Narrowing down who qualifies — and who does not — is more useful than any general success rate.

The patient profile most likely to benefit from ChondroFiller injection in the hip meets all of the following: an ICRS Grade III or IV focal cartilage defect, a defect area between 2 and 6 cm², joint space that remains visible on X-ray, and documented failure of adequate conservative management such as physiotherapy and activity modification. Each criterion matters: a defect that is too large or too diffuse, or a joint where bone is already meeting bone, takes the procedure outside the evidence-supported range.

Features that currently disqualify a patient include significant joint space narrowing and end-stage bone-on-bone arthritis. The published Mazek 2021 cohort further showed that pre-existing Tönnis grade 2–3 osteoarthritis was associated with poor outcomes — a finding that applies specifically to the study's treatment conditions and should inform assessment for all presentations with advanced baseline OA.

The evidence gap that matters most for older patients

There are currently no prospective trials specifically in patients aged 65 or older, or in those with Kellgren-Lawrence Grade III/IV OA, receiving ChondroFiller by the injectable route. Patients choosing this pathway in that population are doing so on mechanistic rationale and clinical experience — not RCT evidence. That is an honest position, not a reason to dismiss the option, but it is one that warrants transparent discussion at consultation.

On timeline: ChondroFiller injection initiates a biological repair process. Scaffold integration and tissue maturation take months, with MRI assessment at 12 months the standard method for confirming how well the scaffold has incorporated.

Getting assessed for ChondroFiller injection in London

ChondroFiller injection is delivered in the UK at the London Cartilage Clinic on Harley Street, the country's certified delivery centre for the product. The service is led by Professor Paul Y. F. Lee, whose experience in image-guided placement is directly relevant to outcome quality — with a scaffold product, how it is placed matters as much as what is placed.

ChondroFiller is imported from Germany (Meidrix Biomedicals GmbH) under individual prescription. It is not available on the NHS, and neither Bupa nor AXA currently covers it, so patients access it entirely on a self-funded basis. Guide costs range from approximately £3,000 for a single-injection protocol to £11,000 for a combined protocol with structured maintenance; the clinic confirms exact costs at assessment.

The first step is a cartilage assessment — clinical history, imaging review, and a candid discussion about defect characteristics, joint space, and whether the patient's goals are realistic given what the joint shows. That assessment is the piece of evidence no published cohort can supply for any individual: how the joint looks now, and whether the window for preservation is still open. As the earlier sections make plain, the outcome data depend heavily on that distinction — between a focal lesion amenable to scaffold repair and diffuse end-stage wear that falls outside what ChondroFiller injection can usefully address. The consultation exists to answer that question honestly before any treatment is planned.

Assessments can be booked at londoncartilage.com.